Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2025 earnings results today. Reported sales increased 9.1% year-over-year to $24.56 billion. Operational sales growth was 7.1%. GAAP net earnings increased 49% to $5.1 billion, or $2.10 per share, compared to last year. Adjusted EPS grew 20.6% to $2.46. For the full year of 2026, JNJ […]
Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2025 earnings results today. Reported sales increased 9.1% year-over-year to $24.56 billion. Operational sales growth was 7.1%. GAAP net earnings increased 49% to $5.1 billion, or $2.10 per share, compared to last year. Adjusted EPS grew 20.6% to $2.46. For the full year of 2026, JNJ […]
Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2025 earnings results today.
Reported sales increased 9.1% year-over-year to $24.56 billion. Operational sales growth was 7.1%.
GAAP net earnings increased 49% to $5.1 billion, or $2.10 per share, compared to last year. Adjusted EPS grew 20.6% to $2.46.
For the full year of 2026, JNJ expects reported sales of $100-101 billion and adjusted EPS of $11.43-11.63.
